Rubric Capital Management (New York)’s Abeona Therapeutics ABEO Stock Holding History

Rubric Capital Management (New York)’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.76M	Buy	+608,771	New	+$3.34M	0.03%	82

Other funds holding ABEO

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rubric Capital Management (New York)'s ABEO Position: Q2 2026 in Review

Rubric Capital Management (New York) opened a new position in Abeona Therapeutics (ABEO) in Q2 2026: 608,771 shares worth $3.76M. The stake represents 0.03% of the portfolio and ranks #82 among its holdings.

126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

Rubric Capital Management (New York) held 608,771 shares of Abeona Therapeutics worth $3.76M as of Q2 2026.
Abeona Therapeutics was a new Rubric Capital Management (New York) position in Q2 2026.
Abeona Therapeutics made up 0.03% of Rubric Capital Management (New York)'s portfolio in Q2 2026, its #82 holding.
126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.